ER and PR Immunohistochemistry and HER2 FISH versus Oncotype DX: Implications for Breast Cancer Treatment

被引:30
|
作者
Park, MiHee M. [1 ]
Ebel, Joshua J. [1 ]
Zhao, Weiquiang [1 ]
Zynger, Debra L. [1 ]
机构
[1] Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA
来源
BREAST JOURNAL | 2014年 / 20卷 / 01期
关键词
breast cancer; estrogen receptor; human epidermal growth factor; immunohistochemistry; oncotype DX; RT-PCR; POLYMERASE CHAIN-REACTION; IN-SITU HYBRIDIZATION; ESTROGEN-RECEPTOR; PCR ASSAY; RECURRENCE;
D O I
10.1111/tbj.12223
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor (HER2) concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and Oncotype DX, a commercially available RT-PCR-based assay which recently began reporting biomarker results was assessed. ER concordance was 98.9% (262/265), Pearson correlation coefficient (r)=0.42, and Spearman's rank correlation ()=0.25. Positive percent agreement for ER was 98.9% (262/265). One patient with discordant ER results was not offered hormone therapy based on the preferential use of Oncotype DX. PR was concordant in 91.3% (242/265), r=0.80, =0.75, and Cohen's kappa ()=0.63. Positive percent agreement for PR was 90.5% (218/241) and negative percent agreement was 100% (24/24). HER2 concordance was 99.2% (245/247), r=0.35, =0.28, and =0.12. Positive percent agreement for HER2 was 0% (0/2) and negative percent agreement was 100% (245/245). Of the three FISH HER2-amplified cases, two were negative and one was equivocal, and all FISH HER2-equivocal cases (n=3) were negative by Oncotype DX. Patients that were FISH HER2-amplified, Oncotype DX HER2-negative did not receive trastuzumab. Although our results demonstrated high concordance between IHC and Oncotype DX for ER and PR, our data showed poor positive percent agreement for HER2. Compared to FISH, Oncotype DX does not identify HER2-positive breast carcinomas. The preferential use of Oncotype DX biomarker results over IHC and FISH is discouraged.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 50 条
  • [31] Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
    Jung, Jaehag
    Lee, Seung Hoon
    Park, Mira
    Youn, Ji Hye
    Shin, Sang Hoon
    Gwak, Ho Shin
    Yoo, Heon
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 295 - 302
  • [32] Effect of EDTA Decalcification on ER and PR Immunohistochemistry and HER2/neu Fluorescence In Situ Hybridization in Breast Carcinoma
    Washburn, Erik
    Tang, Xiaoyu
    Caruso, Carla
    Walls, Michelle
    Han, Bing
    LABORATORY INVESTIGATION, 2019, 99
  • [33] Effect of EDTA Decalcification on ER and PR Immunohistochemistry and HER2/neu Fluorescence In Situ Hybridization in Breast Carcinoma
    Washburn, Erik
    Tang, Xiaoyu
    Caruso, Carla
    Walls, Michelle
    Han, Bing
    MODERN PATHOLOGY, 2019, 32
  • [34] Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx
    Sughayer, Maher A.
    Alhassoon, Sallam
    Sughayer, Haytham M.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 47
  • [35] Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2-Breast Cancer
    Song, Ran
    Lee, Dong-Eun
    Lee, Eun-Gyeong
    Lee, Seeyoun
    Kang, Han-Sung
    Han, Jai Hong
    Lee, Keun Seok
    Sim, Sung Hoon
    Chae, Heejung
    Kwon, Youngmee
    Woo, Jaeyeon
    Jung, So-Youn
    CANCERS, 2023, 15 (18)
  • [36] HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+Breast Cancer With Early Recurrence
    Yamashita, Hiroko
    Ishida, Naoko
    Hatanaka, Yutaka
    Hagio, Kanako
    Oshino, Tomohiro
    Takeshita, Takashi
    Kanno-Okada, Hiromi
    Shimizu, Ai
    Hatanaka, Kanako C.
    Matsuno, Yoshihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 645 - 652
  • [37] Comparison of Expression of ER, PR and HER2 by Immunohistochemistry in Cytology FNA Block Preparations to Surgical Tissue Blocks in Breast Cancer Patients
    Harigopal, M.
    Levy, G.
    Adeniran, A.
    Kowalski, D.
    Chhieng, D.
    Rimm, D. L.
    MODERN PATHOLOGY, 2010, 23 : 93A - 94A
  • [38] Comparison of Expression of ER, PR and HER2 by Immunohistochemistry in Cytology FNA Block Preparations to Surgical Tissue Blocks in Breast Cancer Patients
    Harigopal, M.
    Levy, G.
    Adeniran, A.
    Kowalski, D.
    Chhieng, D.
    Rimm, D. L.
    LABORATORY INVESTIGATION, 2010, 90 : 93A - 94A
  • [39] HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death
    Baehner, F. L.
    Achacoso, N. S.
    Maddala, T.
    Alexander, C.
    Shak, S.
    Quesenberry, C. P.
    Goldstein, L. C.
    Gown, A. M.
    Habel, L. A.
    BREAST CANCER RESEARCH, 2009, 11 : S11 - S11
  • [40] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A